A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI®
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The objectives of the study are to demonstrate that Tobrineb®/Actitob®/Bramitob® is
non-inferior to TOBI® in the primary efficacy variable, forced expiratory volume in one
second (FEV1) percent of predicted normal, and to compare the safety in participants with
cystic fibrosis and chronic infection of the lungs with Pseudomonas aeruginosa.